Analysis of GP73 in patients with HCC as a function of anti-cancer treatment

Article type: Research Article

Authors: Hann, Hie-Won^a | Wang, Mengjun^b | Hafner, Julie^c | Long, Ronald E.^b | Kim, Su Hee^a | Ahn, Meejin^a | Park, Susan^a | Comunale, Mary Ann^b | Block, Timothy M.^b | Mehta, Anand^{b; *}

Affiliations: [a] Liver Disease Prevention Center, Division of Gastroenterology and Hepatology, Jefferson Medical College, Thomas Jefferson University Hospital, Philadelphia, PA, USA | [b] Drexel University College of Medicine, Doylestown, PA, USA | [c] Immunotope Inc., Doylestown, PA, USA

Correspondence: [*] Corresponding author: Dr. Anand Mehta, Department of Microbiology and Immunology, 3805 Old Easton Road, Doylestown, PA 18902, USA. Tel.: +1 215 489 495; Fax: +1 215 489 4920; E-mail: anand.mehta@drexelmed.edu.

Abstract: In this study, we examined the level of Golgi protein 73 (GP73) in the serum of 9 patients as a function of anti-liver cancer treatment. Although the numbers are small, a clear trend was observed. Patients who remained tumor free (up to 6 years post-treatment) showed reductions in GP73 at the first time point available post-treatment. In contrast, patients who had high levels GP73 post treatment all had re-occurrence within a 5 year period. These data are preliminary but dramatically imply that this marker may have value in the monitoring of HCC patients and may be elevated even when small, undetectable tumors are present.

DOI: 10.3233/CBM-2010-0190

Journal: Cancer Biomarkers, vol. 7, no. 6, pp. 269-273, 2010